Trastuzumab: A Cardiologist’s Perspective
Ctr. Malad Sein Deschenes Fabia, University Laval, CHAUQ, Quebec City, PQ, Canada
Curr. Oncol. 2008, 15(3), 162-163; https://doi.org/10.3747/co.v15i3.300
Submission received: 4 March 2008
/
Revised: 5 April 2008
/
Accepted: 6 May 2008
/
Published: 1 June 2008
Abstract
A review of the randomized clinical trials of adjuvant trastuzumab in human epidermal growth factor receptor (HER2)—positive breast cancer demonstrates the great benefit of this monoclonal antibody whose potential cardiotoxicity is a fascinating problem for the cardiologist 1. [...]
Share and Cite
MDPI and ACS Style
Côté, M.A. Trastuzumab: A Cardiologist’s Perspective. Curr. Oncol. 2008, 15, 162-163. https://doi.org/10.3747/co.v15i3.300
AMA Style
Côté MA. Trastuzumab: A Cardiologist’s Perspective. Current Oncology. 2008; 15(3):162-163. https://doi.org/10.3747/co.v15i3.300
Chicago/Turabian StyleCôté, Marc André. 2008. "Trastuzumab: A Cardiologist’s Perspective" Current Oncology 15, no. 3: 162-163. https://doi.org/10.3747/co.v15i3.300
